ECM remodelling in IBD: Innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation

Gut

Volumn 64, Issue 3, 2015, Pages 367-372

  Shimshoni, Elee ^a   Yablecovitch, Doron ^a,b   Baram, Liran ^c   Dotan, Iris ^c   Sagi, Irit ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CELL DAMAGE; CELL FUNCTION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TISSUE INJURY; ANIMAL; INFLAMMATION; INTESTINE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINES;

EID: 84922380038     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308048     Document Type: Article

References (76)

1. Molodecky NA, Soon IS, Rabi D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142:46-54.e42; quiz e30.
2. Qin X. Etiology of inflammatory bowel disease: a unified hypothesis. World J Gastroenterol 2012; 18:1708.
3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474:307-17.
4. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361:2066-78.
5. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-29.
6. Rieder F, Fiocchi C. Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009; 6:228-35.
7. Latella G, Rogler G, Bamias G., et al. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis 2014; 8:1147-65.
8. Rieder F, de Bruyn JR, Pham BT, et al. Results of the 4th Scientific Workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis 2014; 8:1166-78.
9. Nielsen OH, Rogler G, Hahnloser D., et al. Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol 2009; 6:92-106.
10. Ingle SB, Adgaonkar BD, Hinge CR. Microscopic colitis: common cause of unexplained nonbloody diarrhea. World J Gastrointest Pathophysiol 2014; 5:48-53. http://www.wjgnet.com/2150-5330/pdf/v5/i1/48.pdf (accessed 22 Jun 2014).
11. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci 2010; 123:4195-200.
12. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003; 200:423-8.
13. Georges PC, Hui J-J, Gombos Z, et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 293:G1147-54.
14. Johnson LA, Rodansky ES, Sauder K.L., et al. Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts. Inflamm Bowel Dis 2013; 19:891-903.
15. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326:1216-19.
16. Adair-Kirk TL, Senior RM. Fragments of extracellular matrix as mediators of inflammation. Int J Biochem Cell Biol 2008; 40:1101-10.
17. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8:221-33.
18. Massova I, Kotra LP, Fridman R, et al. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 1998; 12:1075-95.
19. Lu P, Takai K, Weaver V.M., et al. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 2011; 3. pii: a005058.
20. Pradeep C-R, Zeisel A., Köstler WJ, et al. Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. Oncogene 2012; 31:3569-83.
21. Waterman M, Ben-Izhak O, Eliakim R., et al. Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 2007; 20:8-14.
22. Lerner I, Hermano E, Zcharia E., et al. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 2011; 121:1709-21.
23. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R., et al. Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. World J Gastroenterol 2003; 9:2843-5. http://www.ncbi.nlm.nih.gov/pubmed/14669348
24. Kofla-Dlubacz A, Matusiewicz M, Krzystek-Korpacka M, et al. Correlation of MMP-3 and MMP-9 with crohn's disease activity in children. Dig Dis Sci 2012; 57:706-12.
25. Vandenbroucke RE, Dejonckheere E, Van Hauwermeiren F, et al. Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol Med 2013; 5:932-48.
26. Wilson CL, Ouellette AJ, Satchell D.P., et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999; 286:113-17.
27. Monteleone I, Federici M, Sarra M., et al. Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. Gastroenterology 2012; 143:1277-87.e1-4.
28. Koller FL, Dozier EA, Nam K.T., et al. Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia. Lab Invest 2012; 92:1749-59.
29. Baugh MD, Perry MJ, Hollander A.P., et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999; 117:814-22.
30. Bailey CJ, Hembry RM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994; 47:113-16.
31. Gao Q, Meijer MJW, Kubben FJGM, et al. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 2005; 37:584-92.
32. Meijer MJW, Mieremet-Ooms MAC, van der Zon AM, et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007; 39:733-9.
33. Pedersen G, Saermark T, Kirkegaard T., et al. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol 2009; 155:257-65.
34. Kirkegaard T, Hansen A, Bruun E., et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004; 53:701-9.
35. Efsen E, Saermark T, Hansen A., et al. Ramiprilate inhibits functional matrix metalloproteinase activity in Crohn's disease fistulas. Basic Clin Pharmacol Toxicol 2011; 109:208-16.
36. Manfredi MA, Zurakowski D, Rufo P.A., et al. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1091-6. http://www.scopus.com/inward/record.url?eid=2-s2.0-49749130444&partnerID=40&md5= 24e8f35c509c85537d05c5c0ebffcb95
37. Annahazi A, Molnar T, Farkas K., et al. Fecal MMP-9: A new noninvasive differential diagnostic and activity marker in ulcerative colitis. J. Crohn's Colitis. 2012; 6:316-20.
38. Kolho K, Sipponen T, Valtonen E. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis 2014; 29:43-50.
39. Gao Q, Meijer MJW, Schluter UG, et al. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 2007; 13:693-702.
40. Faubion WA, Fletcher JG, O'Byrne S, et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol 2013; 108:1891-900.
41. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 2005; 129:1991-2008.
42. Garg P, Vijay-Kumar M, Wang L., et al. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol 2009; 296:G175-84.
43. Santana A, Medina C, Paz-Cabrera M-C, et al. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol 2006; 12:6464-72.
44. Rodrigues DM, Sousa AJ, Hawley S.P., et al. Matrix metalloproteinase 9 contributes to gut microbe homeostasis in a model of infectious colitis. BMC Microbiol 2012; 12:105.
45. Liu H, Patel NR, Walter L, et al. Constitutive expression of MMP9 in intestinal epithelium worsens murine acute colitis and is associated with increased levels of proinflammatory cytokine Kc. Am J Physiol Gastrointest Liver Physiol 2013; 304: G793-803.
46. Lohr K, Sardana H, Lee S., et al. Extracellular matrix protein lumican regulates inflammation in a mouse model of colitis. Inflamm Bowel Dis 2012; 18:143-51.
47. Wu F, Vij N, Roberts L., et al. A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. J Biol Chem 2007; 282:26409-17.
48. Takehara M, Nishimura T, Mima S., et al. Effect of claudin expression on paracellular permeability, migration and invasion of colonic cancer cells. Biol Pharm Bull 2009; 32:825-31.
49. Leone AK, Chun JA, Koehler C.L., et al. Effect of proinflammatory cytokines, tumor necrosis factor-alpha and interferon-gamma on epithelial barrier function and matrix metalloproteinase-9 in Madin Darby canine kidney cells. Cell Physiol Biochem 2007; 19:99-112.
50. Xu R, Feng X, Xie X., et al. HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9. Brain Res 2012; 1436:13-19.
51. Zuo J-H, Zhu W., Li M-Y, et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem 2011; 112:2508-17.
52. Vermeer PD, Denker J, Estin M., et al. MMP9 modulates tight junction integrity and cell viability in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 2009; 296:L751-62.
53. Qin W, Lu W, Li H., et al. Melatonin inhibits IL1β-induced MMP9 expression and activity in human umbilical vein endothelial cells by suppressing NF-κB activation. J Endocrinol 2012; 214:145-53.
54. Behzadian MA, Wang XL, Windsor L.J., et al. TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. Invest Ophthalmol Vis Sci 2001; 42:853-9. http://www.ncbi.nlm.nih.gov/pubmed/11222550 (accessed 16 Jun 2014).
55. Borregaard N, Sehested M, Nielsen B.S., et al. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. Blood 1995; 85:812-17.
56. Adhikary S, Yen J-H, Ganea D, et al. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood 2012; 120:3741-9.
57. Rivera E, Flores I, Rivera E., et al. Molecular profiling of a rat model of colitis: validation of known inflammatory genes and identification of novel disease-associated targets. Inflamm Bowel Dis 2006; 12:950-66.
58. Mambetsariev I, Tian Y, Wu T., et al. Stiffness-activated GEF-H1 expression exacerbates LPS-induced lung inflammation. PLoS One 2014; 9: e92670.
59. Gan X, Wong B, Wright S.D., et al. Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli. J Interferon Cytokine Res 2001; 21:93-8.
60. Zhu YK, Liu XD, Skold C.M., et al. Synergistic neutrophil elastase-cytokine interaction degrades collagen in three-dimensional culture. Am J Physiol Lung Cell Mol Physiol 2001; 281:L868-78. http://ajplung.physiology.org/content/281/4/L868 (accessed 16 Jun 2014).
61. Lacraz S, Nicod LP, Chicheportiche R, et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96:2304-10.
62. Van den Steen PE, Proost P, Wuyts A., et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96:2673-81.
63. Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998; 161:3340-6.
64. Xu X, Jackson PL, Tanner S, et al. A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS One 2011; 6:e15781.
65. Koelink PJ, Overbeek SA, Braber S, et al. Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut 2014; 63:578-87.
66. Kessler S, Rho H, West G., et al. Hyaluronan (HA) deposition precedes and promotes leukocyte recruitment in intestinal inflammation. Clin Transl Sci 2008; 1:57-61.
67. Termeer C, Benedix F, Sleeman J., et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195:99-111.
68. De la Motte CA. Hyaluronan in intestinal homeostasis and inflammation: implications for fibrosis. Am J Gastrointest Liver Physiol 2011; 301:945-9.
69. Webber J, Meran S, Steadman R., et al. Hyaluronan orchestrates transforming growth factor-beta1-dependent maintenance of myofibroblast phenotype. J Biol Chem 2009; 284:9083-92.
70. Bollyky PL, Wu RP, Falk B.A., et al. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci USA 2011; 108:7938-43.
71. Magro F, Rodrigues-Pinto E, Coelho R., et al. Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol 2014; 109:1026-36.
72. Makitalo L, Sipponen T, Karkkainen P., et al. Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis 2009; 24:1157-67.
73. Geboes K, Rutgeerts P, Opdenakker G., et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr Med Res Opin 2005; 21:1741-54.
74. De Bruyn M, Arijs I, Wollants W-J, et al. Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2014; 20:1198-207.
75. Sela-Passwell N, Kikkeri R, Dym O., et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med 2012; 18:143-7.
76. Chen H, Mahaseth M, Zhang Y. Hyaluronic acid as a rescue therapy for trinitrobenzene sulfonic acid-induced colitis through Cox-2 and PGE2 in a Toll-like receptor 4-dependent way. J Zhejiang Univ Sci B 2011; 12:712-19.